Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.66 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.66 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.54 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | SLC1A5 | Q15758 | 7/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7044835 | 0.85 | BCHE (0.53) | DPP7DPP8DPP9POLBKMT2A | |
| SCHEMBL209926 | 0.85 | SIGMAR1 (0.54) | DPP7DPP8DPP9POLBKMT2A | |
| SCHEMBL21054744 | 0.85 | SIGMAR1 (0.54) | DPP7DPP8DPP9POLBKMT2A | |
| SCHEMBL23656532 | 0.82 | FOLH1 (0.60) | DPP7DPP8DPP9POLBKMT2A | |
| SCHEMBL27462545 | 0.82 | LPAR1 (0.49) | DPP7DPP8DPP9HDAC3HDAC1 | |
| SCHEMBL6172479 | 0.81 | DPP7 (0.76) | DPP7DPP8DPP9HDAC3HDAC1 | |
| SCHEMBL12977607 | 0.80 | SLC1A5 (0.60) | DPP7DPP8DPP9HDAC3HDAC1 | |
| SCHEMBL996075 | 0.80 | SLC1A5 (0.60) | DPP7DPP8DPP9HDAC3HDAC1 | |
| Hydrochloric Acid SCHEMBL7043275 | 0.79 | KDM4A (0.50) | DPP7DPP8DPP9KMT2AALPI | |
| SCHEMBL2237757 | 0.79 | SLC1A5 (0.47) | DPP7DPP8DPP9POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1290 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1163262-B1 | PHENYLALANINE DERIVATIVES | US GOV HEALTH & HUMAN SERV (US) | 2011-05-11 | — | — | EP | claimed |
| US-20080139456-A1 | Macrocyclic Sh2 Domain Binding Inhibitors | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2008-06-12 | — | — | US | claimed |
| WO-2008067270-A1 | MACROCYCLIC GRB2 SH2 DOMAIN-BINDING INHIBITORS | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-06-05 | — | — | WO | claimed |
| EP-1793843-A1 | MACROCYCLIC SH2 DOMAIN BINDING INHIBITORS | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services (US) | 2007-06-13 | — | — | EP | claimed |
| US-7226991-B1 | inhibiting SH2 domain binding with a phosphoprotein; to inhibit proliferation of tumor cells; for inhibiting the growth of human breast cancer cells | UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-06-05 | — | — | US | claimed |
| WO-2006039527-A1 | MACROCYCLIC SH2 DOMAIN BINDING INHIBITORS | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-04-13 | — | — | WO | claimed |
| US-6977241-B2 | SH2 domain binding inhibitors | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2005-12-20 | — | — | US | claimed |
| US-20040048788-A1 | Sh2 domain binding inhibitors | DEPARTMENT OF HEALTH AND HUMAN SERVICES, UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, OF THE | 2004-03-11 | — | — | US | claimed |
| EP-1383792-A2 | SH2 DOMAIN BINDING INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-01-28 | — | — | EP | claimed |
| WO-2004003005-A2 | SH2 DOMAIN BINDING INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-01-08 | — | — | WO | claimed |
| WO-2002016407-A2 | SH2 DOMAIN BINDING INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-02-28 | — | — | WO | claimed |
| EP-1163262-A1 | PHENYLALANINE DERIVATIVES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-12-19 | — | — | EP | claimed |
| WO-2000056760-A1 | PHENYLALANINE DERIVATIVES | THE UNITED STATES OF AMERICA, REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-09-28 | — | — | WO | claimed |
| WO-1997007131-A1 | ACYLATED OLIGOPEPTIDES CONTAINING PHOSPHOTYROSINE AS INHIBITORS OF PROTEIN TYROSINE KINASES | NOVARTIS AG (CH) | 1997-02-27 | — | — | WO | claimed |
| US-20260146073-A1 | T CELL RECEPTORS TARGETING MUTATED CDKN2A | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4748856-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH SELF-DRIVING CHIMERIC ANTIGEN RECEPTORS | Lentigen Technology, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747362-A2 | METHODS FOR RAPID MANUFACTURE OF ENGINEERED T CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS | Kyverna Therapeutics, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| US-6307090-B1 | OXALYL ENDCAPPED; CONTAINING A BIVALENT RADICAL OF PHOSPHOTYROSINE OR A PHOSPHOTYROSINE MIMETIC | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-10-23 | — | — | US | disclosed |
| WO-2000056760-A1 | PHENYLALANINE DERIVATIVES | THE UNITED STATES OF AMERICA, REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-09-28 | — | — | WO | disclosed |
| WO-1997007131-A1 | ACYLATED OLIGOPEPTIDES CONTAINING PHOSPHOTYROSINE AS INHIBITORS OF PROTEIN TYROSINE KINASES | NOVARTIS AG (CH) | 1997-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146073-A1 | T CELL RECEPTORS TARGETING MUTATED CDKN2A | TP53, CD74, HLA-C | DPP7 3994/4885DPP8 3317/4885DPP9 3267/4885 |
| US-20080139456-A1 | Macrocyclic Sh2 Domain Binding Inhibitors | ACP1, PPM1D, LASP1 | DPP7 1369/4885DPP8 1610/4885DPP9 1626/4885 |
| US-20040048788-A1 | Sh2 domain binding inhibitors | ACP1, PHLPP1, SORBS1 | DPP7 2408/4885DPP8 2565/4885DPP9 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.